Ouro Fino Saúde Animal Participações (OFSA3) Q1 2026 earnings summary

Executive summary

• Consolidated net revenue rose 32.1% year-over-year to R$250.5 million in Q1 2026, reflecting strong growth from innovation, new product launches, and the full integration of domestic operations post-merger.

• Gross profit increased 46.9% to R$134.9 million, with gross margin up 5.4 p.p. to 53.9%.

• Adjusted EBITDA surged 139.0% to R$44.6 million, with margin expanding 7.9 p.p. to 17.8%.

• Net income for the quarter was R$21.4 million, up from R$2.0 million in Q1 2025.

• Launched a new institutional brand campaign and continued disciplined capital allocation, enabling dividend payments and sustainable cash management.

Financial highlights

• Net revenue: R$250.5 million (+32.1% vs. 1Q25).

• Gross profit: R$134.9 million (+46.9% vs. 1Q25), gross margin: 53.9% (+5.4 p.p. vs. 1Q25).

• Adjusted EBITDA: R$44.6 million (+139.0% vs. 1Q25), margin: 17.8% (+7.9 p.p. vs. 1Q25).

• Adjusted net income: R$20.8 million (+902.7% vs. 1Q25), net margin: 8.3% (+7.2 p.p. vs. 1Q25).

• Cash and equivalents at quarter-end were R$401.1 million, up from R$250.8 million at the end of 2025.

Outlook and guidance

• Strategic plan through 2030 focuses on innovation, operational efficiency, disciplined capital allocation, and international expansion.

• Expectation of further growth in profitability and revenue, supported by ongoing innovation and international expansion.

• Management highlights ongoing investments in R&D and commercial structures to support future growth.

• No material impacts from ongoing tax reform reflected in Q1 2026 results; future impacts will be assessed as regulation is finalized.